Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864

Correspondence - Tranexamic acid for traumatic brain injury

(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894

Science

(2023) · doi:10.1126/science · Cited by 6,063

Global prevalence of dementia: a Delphi consensus study

Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336

American Journal of Pathology

(2015) · American Journal Of Pathology · doi:10.2353/ajpath · Cited by 4,961

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744

Network pharmacology: the next paradigm in drug discovery

Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622

Atomic Structure of Acetylcholinesterase from Torpedo californica : A Prototypic Acetylcholine-Binding Protein

Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991) · Science · doi:10.1126/science.1678899 · Cited by 2,740

The cholinergic hypothesis of Alzheimer’s disease: A review of progress

Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 3×

Intracellular amyloid-β in Alzheimer's disease

LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942

Oxidative Damage Is the Earliest Event in Alzheimer Disease

Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885

Oxidative stress in neurodegeneration: Cause or consequence?

Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869

Alzheimer Mechanisms and Therapeutic Strategies

Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease

Tang, M., Jacobs, D. M., Stern, Y., Marder, K. S., Schofield, P., Gurland, B. J., Andrews, H., & Mayeux, R. P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03356-9 · Cited by 1,647

Regulation of NMDA receptor trafficking by amyloid-β

Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 1×

Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity

Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438

Adenosine Receptors as Therapeutic Targets

Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431

Alzheimer’s Disease: The Challenge of the Second Century

Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424

Mitochondrial abnormalities in Alzheimer's disease

Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356

Recovery of learning and memory is associated with chromatin remodelling

Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007) · Nature · doi:10.1038/nature05772 · Cited by 1,227

Alzheimer’s disease: Clinical trials and drug development

Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217

Multi-target-Directed Ligands To Combat Neurodegenerative Diseases

Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152

Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme

Inestrosa, N. C., Alvarez, A. R., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C. A., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,117

ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models

Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050

The cholinergic system in aging and neuronal degeneration

Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047

EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity

Bieschke, J., Russ, J., Friedrich, R. P., Ehrnhoefer, D. E., Wobst, H. J., Neugebauer, K., & Wanker, E. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910723107 · Cited by 1,044

Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033

Structure and dynamics of molecular networks: A novel paradigm of drug discovery

Csermely, P., Korcsmáros, T., Kiss, H., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 911

S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration

Uehara, T., Nakamura, T., Yao, D., Shi, Z., Gu, Z., Ma, Y., Masliah, E., Nomura, Y., & Lipton, S. A. (2006) · Nature · doi:10.1038/nature04782 · Cited by 905

Release of Alzheimer Amyloid Precursor Derivatives Stimulated by Activation of Muscarinic Acetylcholine Receptors

Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898

Neurobiology of butyrylcholinesterase

Darvesh, S., Hopkins, D. A., & Geula, C. (2003) · Nature reviews. Neuroscience · doi:10.1038/nrn1035 · Cited by 896

Oxidative Stress and Neurotoxicity

Sayre, L. M., Perry, G. L., & Smith, M. A. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700210j · Cited by 884

Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau

Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881

Senile dementia of the Alzheimer type

Terry, R. D., & Katzman, R. (1983) · Annals of Neurology · doi:10.1002/ana.410140502 · Cited by 839

The Genetics of Alzheimer Disease: Back to the Future

Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834

The efficiency of multi-target drugs: the network approach might help drug design

CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803

The Genetics of Alzheimer's Disease

Bertram, L., & Tanzi, R. E. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 794

From magic bullets to designed multiple ligands

Morphy, R., Kay, C., & Ranković, Z. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03163-0 · Cited by 738

Review: Alzheimer's Amyloid β-Peptide-Associated Free Radical Oxidative Stress and Neurotoxicity

Varadarajan, S., Yatin, S., Aksenova, M., & Butterfield, D. A. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4274 · Cited by 735

The genetics of Alzheimer disease

Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727

Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715

A network dysfunction perspective on neurodegenerative diseases

Palop, J. J., Chin, J., & Mucke, L. (2006) · Nature · doi:10.1038/nature05289 · Cited by 710

Control of Peripheral Nerve Myelination by the ß-Secretase BACE1

Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703

Delayed Reduction of Ischemic Brain Injury and Neurological Deficits in Mice Lacking the Inducible Nitric Oxide Synthase Gene

Iadecola, C., Zhang, F., Casey, R., Nagayama, M., & Ross, M. E. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-23-09157.1997 · Cited by 661

Cannabinoid CB2Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains

Benito, C., Núñez, E., Tolón, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., & Romero, J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-35-11136.2003 · Cited by 636

Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies

Sarkar, S., Ravikumar, B., Floto, R. A., & Rubinsztein, D. C. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.110 · Cited by 578

A review on coumarins as acetylcholinesterase inhibitors for Alzheimer’s disease

Anand, P., Singh, B., & Singh, N. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.042 · Cited by 530

Toll-like receptor signaling in neural plasticity and disease

Okun, E., Griffioen, K. J. S., & Mattson, M. P. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.02.005 · Cited by 529

Inflammatory Neurodegeneration and Mechanisms of Microglial Killing of Neurons

Brown, G. C., & Neher, J. J. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8105-9 · Cited by 526

Alzheimer's disease – do tauists and baptists finally shake hands?

Mudher, A. K., & Lovestone, S. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02031-2 · Cited by 523

beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies.

Bartolini, M., Bertucci, C., Cavrini, V., & Andrisano, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01514-9 · Cited by 523

Alzheimer's disease, β‐amyloid, glutamate, NMDA receptors and memantine – searching for the connections

Danysz, W., & Parsons, C. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02057.x · Cited by 500

Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models

Baum, L., & Ng, A. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6403 · Cited by 483

The importance of neuritic plaques and tangles to the development and evolution of AD

Tiraboschi, P., Hansen, L. A., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000129697.01779.0a · Cited by 477

Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures

Nagayama, T., Sinor, A. D., Simon, R. P., Chen, J., Graham, S. H., Jin, K., & Greenberg, D. A. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-08-02987.1999 · Cited by 468

Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process

De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455

REVIEW: Curcumin and Alzheimer’s disease

Hamaguchi, T., Ono, K., & Yamada, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00147.x · Cited by 450

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440

Synapses and Alzheimer's Disease

Sheng, M., Sabatini, B. L., & Sudhof, T. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005777 · Cited by 436

Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer’s disease ameliorates amyloid pathologies and memory deficits

Yang, D.-S., Stavrides, P., Mohan, P. S., Kaushik, S., Kumar, A., Ohno, M., Schmidt, S. D., Wesson, D., Bandyopadhyay, U., Jiang, Y., et al. (2011) · Brain · doi:10.1093/brain/awq341 · Cited by 429

“Lest we forget you — methylene blue …”

Schirmer, R. H., Adler, H., Pickhardt, M., & Mandelkow�, E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.012 · Cited by 425

Botulinum Neurotoxin: A Marvel of Protein Design

Montal, M. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.051908.125345 · Cited by 425

Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model

Ricobaraza, A., Cuadrado-Tejedor, M., Pérez-Mediavilla, A., Frechilla, D., Del Río, J., & García-Osta, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.229 · Cited by 423

PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses

Faux, N. G., Ritchie, C. W., Gunn, A. P., Rembach, A., Tsatsanis, A., Bedő, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1390 · Cited by 406

Phenolic Compounds Prevent Alzheimer’s Pathology through Different Effects on the Amyloid-β Aggregation Pathway

Hamaguchi, T., Ono, K., Murase, A., & Yamada, M. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090417 · Cited by 403

The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice

Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., Hogan, A.-M. L., Xie, S. X., Ballatore, C., Smith, A. B., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4922-11.2012 · Cited by 401

Phospholipase A2 in the central nervous system

Sun, G. Y., Xu, J., Jensen, M. D., & Simonyi, Á. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r300016-jlr200 · Cited by 391

Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver

Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390

Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation

Ehrhart, J. C., Obregon, D. F., Mori, T., Hou, H., Sun, N., Bai, Y., Klein, T., Fernandez, F., Tan, J., & Shytle, R. D. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-29 · Cited by 386

Crosstalk between Nitric Oxide and Zinc Pathways to Neuronal Cell Death Involving Mitochondrial Dysfunction and p38-Activated K+ Channels

Bossy‐Wetzel, E., Talantova, M. V., Lee, W. D., Schölzke, M. N., Harrop, A., Mathews, E. A., Götz, T., Han, J., Ellisman, M. H., Perkins, G. A., et al. (2004) · Neuron · doi:10.1016/s0896-6273(04)00015-7 · Cited by 385

Vascular Pathology in Alzheimer Disease: Correlation of Cerebral Amyloid Angiopathy and Arteriosclerosis/Lipohyalinosis with Cognitive Decline

Thal, D. R., Ghebremedhin, E., Orantes, M., & Wiestler, O. D. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.12.1287 · Cited by 384

Alzheimer's DiseasePreprint

Selkoe, D. J. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004457 · Cited by 383

The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons.

Skaper, S. D., Buriani, A., Toso, R. D., Petrelli, L., Romanello, S., Facci, L., & Leon, A. A. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3984 · Cited by 379

Alzheimer's disease, metal ions and metal homeostatic therapy

Zatta, P., Drago, D., Bolognin, S., & Sensi, S. L. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.05.002 · Cited by 369

Cholinesterase Inhibitors Used in the Treatment of Alzheimer???s Disease

Wilkinson, D. G., Francis, P. T., Schwam, E. M., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 367

Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy

Khlistunova, I., Biernat, J., Wang, Y., Pickhardt, M., von Bergen�, M., Gažová, Z., Mandelkow�, E., & Mandelkow, E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507753200 · Cited by 366

Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease

Kar, S., Slowikowski, S. P. M., Westaway, D. A., & Mount, H. T. J. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0442 · Cited by 366

mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies

Caccamo, A., Magrì, A., Medina, D. X., Wisely, E. V., López‐Aranda, M. F., Silva, A. J., & Oddo, S. (2013) · Aging Cell · doi:10.1111/acel.12057 · Cited by 362

Neuroprotective effect of cannabidiol, a non‐psychoactive component from Cannabis sativa, on β‐amyloid‐induced toxicity in PC12 cells

Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361

Current Pharmacotherapy for Alzheimer's Disease

Lleó, A., Greenberg, S. M., & Growdon, J. H. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 347

Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase

Pang, Y., Quiram, P. A., Jelacic, T. M., Hong, F., & Brimijoin, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23646 · Cited by 344

Resveratrol—A boon for treating Alzheimer's disease?

Anekonda, T. S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.04.004 · Cited by 343

Oxidative stress activates a positive feedback between the γ‐ and β‐secretase cleavages of the β‐amyloid precursor protein

Tamagno, E., Guglielmotto, M., Aragno, M., Borghi, R., Autelli, R., Giliberto, L., Muraca, G., Danni, O., Zhu, X., Smith, M. A., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05072.x · Cited by 342

Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

Youdim, M. B. H., Gross, A., & Finberg, J. P. M. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703826 · Cited by 342

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 335

Autophagy: Principles and significance in health and disease

Todde, V., Marten Veenhuis, A., & van der Klei, I. J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.016 · Cited by 332

Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer’s Disease

Brioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., & Cowart, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166876 · Cited by 331

Apolipoprotein E4 Causes Age- and Tau-Dependent Impairment of GABAergic Interneurons, Leading to Learning and Memory Deficits in Mice

Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S. Y., Zwilling, D., Yan, T. X., Chen, L., & Huang, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4040-10.2010 · Cited by 326

Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures

Zheng, W.-H., Bastianetto, S., Mennicken, F., Ma, W., & Kar, S. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00404-9 · Cited by 321

Stable Complexes Involving Acetylcholinesterase and Amyloid-β Peptide Change the Biochemical Properties of the Enzyme and Increase the Neurotoxicity of Alzheimer’s Fibrils

Alvarez, A. R., Alarcón, R., Opazo, C., Campos, E. O., Muñoz, F. J., Calderón, F. H., Dajas, F., Gentry, M. K., Doctor, B. P., Mello, F. G. D., et al. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03213.1998 · Cited by 320

The Revitalized Tau Hypothesis on Alzheimer's Disease

Maccioni, R. B., Farias, G. A., Morales, I., & Navarrete, L. P. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.03.007 · Cited by 316

Caffeine for treatment of Parkinson disease

Postuma, R. B., Lang, A. E., Munhoz, R. P., Charland, K., Pelletier, A., Moscovich, M., Filla, L., Zanatta, D., Romenets, S. R., Altman, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318263570d · Cited by 311

Amyloid‐Beta Interaction with Mitochondria

Pagani, L., & Eckert, A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/925050 · Cited by 309

Anti-Alzheimer and Antioxidant Activities of Coptidis Rhizoma Alkaloids

Jung, H. A., Min, B.-S., Yokozawa, T., Lee, J.-H., Kim, Y. S., & Choi, J. S. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.1433 · Cited by 308

Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation

Feng, Y. N., Wang, X., Yang, S., Wang, Y., Zhang, X., Du, X., Sun, X., Zhao, M., Huang, L., & Liu, R. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.08.013 · Cited by 306

Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease

Xu, Y., Yan, J., Zhou, P., Li, J., Gao, H., Xia, Y., & Wang, Q. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.02.002 · Cited by 304

Allosteric Sensitization of Nicotinic Receptors by Galantamine, a New Treatment Strategy for Alzheimer’s Disease

Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303

Lithium, a Common Drug for Bipolar Disorder Treatment, Regulates Amyloid-β Precursor Protein Processing

Yuan, S., Ryder, J. W., Li, B., Wu, X., Fox, N. W., Solenberg, P., Brune, K. A., Paul, S. M., Zhou, Y., Liu, F., et al. (2004) · Biochemistry · doi:10.1021/bi035627j · Cited by 298

Epigenetic Differences in Cortical Neurons from a Pair of Monozygotic Twins Discordant for Alzheimer's Disease

Mastroeni, D., McKee, A. C., Grover, A., Rogers, J., & Coleman, P. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006617 · Cited by 298

The anti‐amnesic and neuroprotective effects of donepezil against amyloid β25‐35peptide‐induced toxicity in mice involve an interaction with theσ1receptor

Meunier, J., Ieni, J. R., & Maurice, T. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706927 · Cited by 294

Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry

Mendgen, T., Steuer, C., & Klein, C. D. P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201243p · Cited by 292

Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A 2 in cortical neurons

Shelat, P. B., Chalimoniuk, M., Wang, J., Strosznajder, J. B., Lee, J. C., Sun, A. Y., Simonyi, Á., & Sun, G. Y. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05347.x · Cited by 288

GABAergic Interneuron Dysfunction Impairs Hippocampal Neurogenesis in Adult Apolipoprotein E4 Knockin Mice

Li, G., Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Ring, K., Halabisky, B., Deng, C., Mahley, R. W., & Huang, Y. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.10.015 · Cited by 288

Lipoic acid as a novel treatment for Alzheimer's disease and related dementias

Holmquist, L., Stuchbury, G., Berbaum, K., Muscat, S., Young, S. A., Häger, K., Engel, J., & Münch, G. W. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.07.001 · Cited by 286

Nanolipidic particles improve the bioavailability and α-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease

Smith, A., Giunta, B., Bickford, P. C., Fountain, M., Tan, J., & Shytle, R. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.01.012 · Cited by 280

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases

Zheng, H., Weiner, L. M., Bar-Am, O., Epsztejn, S., Cabantchik, Z. I., Warshawsky, A., Youdim, M. B. H., & Fridkin, M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.10.037 · Cited by 278

Monoacylglycerol Lipase Is a Therapeutic Target for Alzheimer's Disease

Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y., Teng, Z., & Chen, C. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.030 · Cited by 277

Recent advances in our understanding of neurodegeneration

Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274

New Tacrine–4-Oxo-4H-chromene Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Cholinergic, Antioxidant, and β-Amyloid-Reducing Properties

Fernández‐Bachiller, M. I., Pérez, C., Monjas, L., Rademann, J., & Rodrı́guez-Franco, M. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201460y · Cited by 271

Novel Tacrine−8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties

Fernández‐Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., Garcı́a, A. G., & Rodrı́guez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 270

Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia

Nordberg, A. K., Alafuzoff, I. I., & Winblad, B. G. (1992) · Journal of Neuroscience Research · doi:10.1002/jnr.490310115 · Cited by 270

A Molecular Link between the Active Component of Marijuana and Alzheimer's Disease Pathology

Eubanks, L. M., Rogers, C. J., Beuscher, Koob, G. F., Olson, A. J., Dickerson, T. J., & Janda, K. D. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060066m · Cited by 270

3-(4-{[Benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) Inhibits Both Acetylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation: A Dual Function Lead for Alzheimer's Disease Therapy

Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., & Recanatini, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0340602 · Cited by 268

High‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D., & Nakagawa, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-150359 · Cited by 264

Epigenetic mechanisms in Alzheimer's disease

Mastroeni, D., Grover, A., Delvaux, E., Whiteside, C. M., Coleman, P. D., & Rogers, J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.017 · Cited by 263

Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease

Ma, T., Hoeffer, C. A., Capetillo-Zarate, E., Yu, F., Wong, H., Lin, M. T., Tampellini, D., Klann, E., Blitzer, R. D., & Gouras, G. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012845 · Cited by 262

Mitochondria-associated ER membranes in Alzheimer disease

Schon, E. A., & Area-Gomez, E. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.07.011 · Cited by 261

Search for natural products related to regeneration of the neuronal network

Tohda, C., Kuboyama, T., & Komatsu, K. (2005) · Neurosignals · doi:10.1159/000085384 · Cited by 257

Phenolic Compounds Prevent Amyloid β-Protein Oligomerization and Synaptic Dysfunction by Site-specific Binding

Ono, K., Li, L., Takamura, Y., Yoshiike, Y., Zhu, L., Han, F., Mao, X., Ikeda, T., Takasaki, J., Nishijo, H., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.325456 · Cited by 255

The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells

Esposito, G., Filippis, D. D., Carnuccio, R., Izzo, A. A., & Iuvone, T. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0025-1 · Cited by 252

Novel Tacrine−Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties

Rodrı́guez-Franco, M. I., Fernández‐Bachiller, M. I., Pérez, C., Hernández‐Ledesma, B., & Bartolomé, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050746d · Cited by 250

Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment

Mangialasche, F., Polidori, M. C., Monastero, R., Ercolani, S., Camarda, C., Cecchetti, R., & Mecocci, P. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.04.002 · Cited by 250

Cannabinoid Receptor Agonists Protect Cultured Rat Hippocampal Neurons from Excitotoxicity

Shen, M., & Thayer, S. A. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.3.459 · Cited by 250

Nutritional influences on epigenetics and age-related disease

Park, L. K., Friso, S., & Choi, S. (2011) · Proceedings of The Nutrition Society · doi:10.1017/s0029665111003302 · Cited by 245

The role of mTOR signaling in Alzheimer disease

Oddo, S. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s310 · Cited by 243

The Spice Sage and Its Active Ingredient Rosmarinic Acid Protect PC12 Cells from Amyloid-β Peptide-Induced Neurotoxicity

Iuvone, T., Filippis, D. D., Esposito, G., D’Amico, A., & Izzo, A. A. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099317 · Cited by 243

Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor

Sugimoto, H., Ogura, H., Arai, Y., Iimura, Y., & Yamanishi, Y. (2002) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.89.7 · Cited by 240

Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development

Floyd, R. A. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00293-7 · Cited by 240

Multi-Target-Directed Ligands in Alzheimer's Disease Treatment

Bajda, M., Guzior, N., Ignasik, M., & Malawska, B. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797535245 · Cited by 240

The future of Alzheimer's disease: The next 10 years

Hampel, H. J., Prvulovic, D., Teipel, S. J., Jessen, F., Luckhaus, C., Frölich, L., Riepe, M. W., Dodel, R. C., Leyhe, T., Bertram, L., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.008 · Cited by 238

Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease

Li, F., Gong, Q., Dong, H., & Shi, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212798919075 · Cited by 231

Therapeutic potential of resveratrol in Alzheimer's disease

Vingtdeux, V., Dreses‐Werringloer, U., Zhao, H., Davies, P. J., & Marambaud, P. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s6 · Cited by 230

Botanical Phenolics and Brain Health

Sun, A. Y., Wang, Q., Simonyi, Á., & Sun, G. Y. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8052-z · Cited by 229

A small‐molecule enhancer of autophagy decreases levels of Aβ and APP‐CTF via Atg5‐dependent autophagy pathway

Tian, Y., Bustos, V., Flajolet, M., & Greengard, P. (2011) · The FASEB Journal · doi:10.1096/fj.10-175158 · Cited by 229

Rational Approach To Discover Multipotent Anti-Alzheimer Drugs

Rosini, M., Andrisano, V., Bartolini, M., Bolognesi, M. L., Hrelia, P., Minarini, A., Tarozzi, A., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049112h · Cited by 228

Benefits from Dietary Polyphenols for Brain Aging and Alzheimer’s Disease

Rossi, L. C., Mazzitelli, S., Arciello, M., Capo, C. R., & Rotilio, G. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9696-7 · Cited by 223

Simultaneous Manipulation of Multiple Brain Targets by Green Tea Catechins: A Potential Neuroprotective Strategy for Alzheimer and Parkinson Diseases

Mandel, S. A., Amit, T., Weinreb, O., Reznichenko, L., & Youdim, M. B. H. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00060.x · Cited by 222

Regulation of Amyloid Precursor Protein Cleavage

Mills, J., & Reiner, P. B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720443.x · Cited by 222

Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors: New Disease-Modifying Agents for Alzheimer's Disease

Muñoz-Ruiz, P., Rubio, L., García‐Palomero, E., Dorronsoro, I., del Monte-Millán, M., Valenzuela, R., Usán, P., de Austria, C., Bartolini, M., Andrisano, V., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503289 · Cited by 221

Nitration of Tau Protein Is Linked to Neurodegeneration in Tauopathies

Horiguchi, T., Uryu, K., Giasson, B. I., Ischiropoulos, H., Lightfoot, R. T., Bellmann, C., Richter‐Landsberg, C., Lee, V. M. ‐., & Trojanowski, J. Q. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63462-1 · Cited by 220

Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer’s Disease

Bolea, I., Juárez‐Jiménez, J., Rı́os, C. D. L., Chioua, M., Pouplana, R., Luque, F. J., Unzeta, M., Marco, J. L., & Samadi, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200853t · Cited by 220

Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease

Chang, J., Rimando, A. M., Pallàs, M., Camins, A., Porquet, D., Reeves, J., Shukitt‐Hale, B., Smith, M. A., Joseph, J. A., & Casadesús, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.015 · Cited by 219

Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

Piazzi, L., Cavalli, A., Colizzi, F., Belluti, F., Bartolini, M., Mancini, F., Recanatini, M., Andrisano, V., & Rampa, A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.100 · Cited by 215

The Non-Amyloidogenic Pathway: Structure and Function of α-Secretases

Kojro, E., & Fahrenholz, F. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_5 · Cited by 211

Progressive accumulation of amyloid‐ β oligomers in Alzheimer’s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins

Pham, E., Crews, L., Ubhi, K., Hansen, L., Adame, A., Cartier, A., Salmon, D., Galasko, D., Michael, S., Savas, J. N., et al. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07719.x · Cited by 206

A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer’s disease

Patil, P. O., Bari, S. B., Firke, S. D., Deshmukh, P. K., DONDA, S. T., & Patil, A. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.017 · Cited by 203

B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-β deposition in mice

Fuso, A., Nicolia, V., Cavallaro, R. A., Ricceri, L., D’Anselmi, F., Coluccia, P., Calamandrei, G., & Scarpa, S. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.12.018 · Cited by 197

A genome-wide scan for common variants affecting the rate of age-related cognitive decline

Jager, P. L. D., Shulman, J. M., Chibnik, L. B., Keenan, B. T., Raj, T., Wilson, R. S., Yu, L., Leurgans, S. E., Tran, D., Aubin, C., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.033 · Cited by 196

Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.

Camps, P., Formosa, X., Galdeano, C., Gómez, T., Muñoz-Torrero, D., Scarpellini, M., Viayna, E., Badía, A., Clos, M. V., Camins, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001313 · Cited by 194

Pathologically-Activated Therapeutics for Neuroprotection: Mechanism of NMDA Receptor Block by Memantine and S-Nitrosylation

Lipton, S. A. (2007) · Current Drug Targets · doi:10.2174/138945007780618472 · Cited by 192

Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates

Fang, L., Kraus, B., Lehmann, J., Heilmann, J., Zhang, Y., & Decker, M. W. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.073 · Cited by 192

Role of Mitochondria in Neurodegenerative Diseases: Mitochondria as a Therapeutic Target in Alzheimer's Disease

Reddy, P. H. (2009) · CNS Spectrums · doi:10.1017/s1092852900024901 · Cited by 192

Green Tea Epigallocatechin-3-Gallate (EGCG) and Other Flavonoids Reduce Alzheimer's Amyloid-Induced Mitochondrial Dysfunction

Dragicevic, N., Smith, A., Lin, X., Yuan, F., Copes, N., Delic, V., Tan, J., Cao, C., Shytle, R. D., & Bradshaw, P. C. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101629 · Cited by 192

Ferulic Acid Is a Nutraceutical β-Secretase Modulator That Improves Behavioral Impairment and Alzheimer-like Pathology in Transgenic Mice

Mori, T., Koyama, N., Guillot‐Sestier, M., Tan, J., & Town, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055774 · Cited by 191

The Ubiquitin-Proteasome System and the Autophagic-Lysosomal System in Alzheimer Disease

Ihara, Y., Morishima-Kawashima, M., & Nixon, R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006361 · Cited by 190

The Role of Phytochemicals in the Treatment and Prevention of Dementia

Howes, M. R., & Perry, E. K. (2011) · Drugs & Aging · doi:10.2165/11591310-000000000-00000 · Cited by 187

Inhibition of Acetylcholinesterase, β-Amyloid Aggregation, and NMDA Receptors in Alzheimer’s Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush

Rosini, M., Simoni, E., Bartolini, M., Cavalli, A., Ceccarini, L., Pascu, N., McClymont, D. W., Tarozzi, A., Bolognesi, M. L., Minarini, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800577j · Cited by 186

Exogenous Anandamide Protects Rat Brain against Acute Neuronal InjuryIn Vivo

van der Stelt, M., Veldhuis, W. B., van Haaften, G. W., Fezza, F., Bisogno, T., Bär, P. R., Veldink, G. A., Vliegenthart, J. F. G., Marzo, V. D., & Nicolay, K. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-22-08765.2001 · Cited by 185

A Small Molecule Targeting the Multifactorial Nature of Alzheimer's Disease

Cavalli, A., Bolognesi, M. L., Capsoni, S., Andrisano, V., Bartolini, M., Margotti, E., Cattaneo, A., Recanatini, M., & Melchiorre, C. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700256 · Cited by 180

β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites

Frost, D., Meechoovet, B., Wang, T., Gately, S. T., Giorgetti, M., Shcherbakova, I. M., & Dunckley, T. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019264 · Cited by 177

Vitamin C and Vitamin E for Alzheimer's Disease

Boothby, L. A., & Doering, P. L. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e495 · Cited by 176

Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-InducedIn VivoExcitotoxicity

van der Stelt, M., Veldhuis, W. B., Bär, P. R., Veldink, G. A., Vliegenthart, J. F. G., & Nicolay, K. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06475.2001 · Cited by 176

TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function.

Benveniste, E. N., & Benos, D. J. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.15.8529837 · Cited by 174

Pyrano[3,2-c]quinoline−6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds

Camps, P., Formosa, X., Galdeano, C., Muñoz‐Torrero, D., Ramírez, L., Gómez, E., Isambert, N., Lavilla, R., Badı́a, A., Clos, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900859q · Cited by 174

Glycogen synthase kinase 3β and Alzheimer’s disease: pathophysiological and therapeutic significance

Balaraman, Y., Limaye, A. R., Levey, A. I., & Srinivasan, S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5597-y · Cited by 172

Mechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications

Khoury, J. E., & Luster, A. D. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.08.004 · Cited by 171

The roles of NADPH oxidase and phospholipases A2in oxidative and inflammatory responses in neurodegenerative diseases

Sun, G. Y., Horrocks, L. A., & Farooqui, A. A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04670.x · Cited by 170

Green tea catechins as a BACE1 (β-Secretase) inhibitor

Jeon, S.-Y., Bae, K., Seong, Y.-H., & Song, K. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.018 · Cited by 168

Update on the Pharmacological Treatment of Alzheimers Disease

Massoud, F., & Gauthier, S. G. (2010) · Current Neuropharmacology · doi:10.2174/157015910790909520 · Cited by 168

Berberine: A Potential Multipotent Natural Product to Combat Alzheimer’s Disease

Ji, H., & Shen, L. (2011) · Molecules · doi:10.3390/molecules16086732 · Cited by 166

Neuroprotective Effects of Resveratrol Against Aβ Administration in Rats are Improved by Lipid-Core Nanocapsules

Frozza, R. L., Bernardi, A., Hoppe, J. B., Meneghetti, A. B., Matté, A., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., & Salbego, C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8401-2 · Cited by 165

Inhibition of Microglial Activation Protects Hippocampal Neurogenesis and Improves Cognitive Deficits in a Transgenic Mouse Model for Alzheimer’s Disease

Biscaro, B., Lindvall, O., Tesco, G., Ekdahl, C. T., & Nitsch, R. M. (2012) · Neurodegenerative Diseases · doi:10.1159/000330363 · Cited by 164

Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons

Chen, H.-K., Liu, Z., Meyer-Franke, A., Brodbeck, J., Miranda, R. D., McGuire, J. G., Pleiss, M. A., Ji, Z.-S., Balestra, M. E., Walker, D. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276162 · Cited by 163

The Toxicity of Amyloid ß Oligomers

Zhao, L. N., Leong, H., Mu, Y., & Chew, L. Y. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13067303 · Cited by 163

Neuroreceptor changes in Alzheimer disease.

Nordberg, A. K. (1992) · PubMed · Cited by 160

Tacrine–Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties

Fernández‐Bachiller, M. I., Pérez, C., Campillo, N. E., Paez, J. A., González-Muñoz, G. C., Usán, P., García‐Palomero, E., López, M. G., Villarroya, M., Garcı́a, A. G., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200800414 · Cited by 160

Resveratrol Inhibits β-Amyloid-Induced Neuronal Apoptosis through Regulation of SIRT1-ROCK1 Signaling Pathway

Feng, X., Liang, N., Zhu, D., Gao, Q., Peng, L., Dong, H., Yue, Q., Liu, H., Bao, L., Zhang, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059888 · Cited by 160

Medicinal Plants and Dementia Therapy: Herbal Hopes for Brain Aging?

Perry, E. K., & Howes, M. R. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00202.x · Cited by 160

What is behind the non-antibiotic properties of minocycline?

Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.006 · Cited by 158

Synthesis, Characterization, and Metal Coordinating Ability of Multifunctional Carbohydrate-Containing Compounds for Alzheimer's Therapy

Storr, T., Merkel, M., Song-Zhao, G. X., Scott, L. E., Green, D. E., Bowen, M. L., Thompson, K. H., Patrick, B. O., Schugar, H. J., & Orvig, C. (2007) · Journal of the American Chemical Society · doi:10.1021/ja068965r · Cited by 156

Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing

Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., Schweighoffer, F., & Désiré, L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05396.x · Cited by 155

A new muscle glycogen storage disease associated with glycogenin-1 deficiency

(2014) · DIAL (Catholic University of Leuven) · doi:10.1002/ana · Cited by 155

Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structure–Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimer’s Disease

Hamann, M. T., Alonso, D. A., Martı́n-Aparicio, E., Fuertes, A., Perez-Puerto, M. J., Castro, A., Morales, S., Navarro, M. L., del Monte-Millán, M., Medina, M., et al. (2007) · Journal of Natural Products · doi:10.1021/np060092r · Cited by 154

Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta‐amyloid‐induced toxicity in PC12 cells

Hoi, C. P., Ho, Y. P., Baum, L., & Chow, A. H. L. (2010) · Phytotherapy Research · doi:10.1002/ptr.3178 · Cited by 154

Validation of a quantitative cerebrospinal fluid \nalpha-synuclein assay in a European-wide interlaboratory study

Kruse, N., Persson, S., Alcolea, D. A., Bahl, J., Baldeiras, I., Capello, E., Chiasserini, D., Emeršič, A., Engelborghs, S., Eren, E., et al. (2015) · IRIS eCampus Telematic University (Università degli Studi eCampus) · doi:10.1016/j.neurobiolaging · Cited by 154

Inhibition of cholinesterase and amyloid‐β aggregation by resveratrol oligomers from Vitis amurensis

Jang, M. H., Piao, X. L., Kim, J., Kwon, S. W., & Park, J. H. (2008) · Phytotherapy Research · doi:10.1002/ptr.2406 · Cited by 153

Hopeahainol A: An Acetylcholinesterase Inhibitor from Hopea hainanensis

Ge, H. M., Zhu, C. H., Shi, D. H., Zhang, L., Xie, D. Q., Yang, J. W., Ng, S. W., & Tan, R. X. (2007) · Chemistry - A European Journal · doi:10.1002/chem.200700960 · Cited by 150

Mammalian Target of Rapamycin: Hitting the Bull′s‐Eye for Neurological Disorders

Chong, Z. Z., Shang, Y., Zhang, L., Wang, S., & Maiese, K. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.6.14787 · Cited by 149

Current and future therapy in Alzheimer’s disease

van Marum, R. J. (2008) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00578.x · Cited by 146

Pharmacological drug treatment of Alzheimer disease: The cholinergic hypothesis revisited

Ladner, C. J., & Lee, J. M. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199808000-00001 · Cited by 142 · cited 2×

Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis

Dedeoglu, A., Cormier, K., Payton, S., Tseitlin, K. A., Kremsky, J. N., Lai, L., Li, X., Moir, R. D., Tanzi, R. E., Bush, A. I., et al. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.08.016 · Cited by 141

Site-Activated Multifunctional Chelator with Acetylcholinesterase and Neuroprotective−Neurorestorative Moieties for Alzheimer’s Therapy

Zheng, H., Youdim, M. B. H., & Fridkin, M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900504c · Cited by 141

Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease

Fisher, A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07507.x · Cited by 140

Berberine suppresses amyloid-beta-induced inflammatory response in microglia by inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signalling pathways

Jia, L., Liu, J., Song, Z., Pan, X., Chen, L., Cui, X. K., & Wang, Μ. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01529.x · Cited by 137

Tacripyrines, the First Tacrine−Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease

Marco, J. L., Leon, R. M., Rı́os, C. D. L., Samadi, A., Bartolini, M., Andrisano, V., Huertas, Ó., Barril, X., Luque, F. J., Rodrı́guez-Franco, M. I., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801292b · Cited by 136

Bivalent β-Carbolines as Potential Multitarget Anti-Alzheimer Agents

Rook, Y. R. N., Schmidtke, K.-U., Gaube, F., Schepmann, D., Wünsch, B., Heilmann, J., Lehmann, J., & Winckler, T. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1000024 · Cited by 135

Mammalian target of rapamycin: A valid therapeutic target through the autophagy pathway for alzheimer's disease?

Cai, Z., Zhao, B., Li, K., Zhang, L., Li, C., Quazi, S. H., & Tan, Y. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23011 · Cited by 134

Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases

Ivasiv, V., Albertini, C., Gonçalves, A. E., Rossi, M., & Bolognesi, M. L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619115735 · Cited by 396

Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases

Makhoba, X. H., Viegas, C., Mosa, R. A., Viegas, F. P. D., & Pooe, O. J. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s257494 · Cited by 337

Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease

Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323

Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents

Jouanne, M., Rault, S., & Voisin‐Chiret, A. S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.070 · Cited by 279

Antibacterial and antioxidant activities for natural and synthetic dual-active compounds

Martelli, G., & Giacomini, D. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.009 · Cited by 232

Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer’s disease. Curr. Neuropharmacol. 12, 2–36. doi: 10.2174/1570159X113116660047 Alzheimer’s Association

Agis-torres, A., Söllhuber, M. M., Fern, M., & Sanchez-montero, J. M. (2014)

Multi-Target-Directed Ligands in Alzheimer’s Disease Therapy

Nepovimová, E., & Kuča, K. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.93269 · Cited by 5

Multi-Target-Directed Ligands in Alzheimer’s Disease Therapy

Kuca, K. (2018) · BiblioBoard Library Catalog (Open Research Library)

Multi Target Directed Ligand for Alzheimer’s Disease: A Review of Therapeutic Strategies and Advances

Kumar, S., Sharma, V., Happy, & Verma, D. K. K. (2026) · Current Pharmaceutical Research · doi:10.63785/cpr.2026.2.2.292310

Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer’s Disease

Kumar, R., Kumar, V., Kumar, B., Thakur, A., & Dwivedi, A. R. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210512005508 · Cited by 55